Introduction
Welcome Message from Activity Director
It is our great pleasure to welcome you to the Cleveland Clinic Abu Dhabi’s 1st International Thoracic Oncology Symposium, taking place in November 2025. This inaugural event will gather leading thoracic surgeons, oncologists, pulmonologists, and radiation oncologists, among other specialities from the United Arab Emirates, the broader Middle East, and around the world.
As the burden of thoracic malignancies continues to rise globally, the need for multidisciplinary collaboration and innovation has never been greater. This symposium aims to provide a comprehensive platform to explore the latest advances in the diagnosis, treatment, and research of thoracic cancers — from lung, mediastinal and pleural tumors to complex surgical interventions and emerging local and systemic therapies.
Our scientific program features high-impact lectures, expert panels, and interactive sessions led by internationally recognized speakers. It is designed to foster collaboration, stimulate discussion, and inspire excellence in thoracic oncology. We are proud to organize this inaugural edition at Cleveland Clinic Abu Dhabi, and we believe it will serve as a unique opportunity to network, exchange knowledge, and strengthen collaborations across regions and specialties
Learning Objectives
- Analyse the application of personalised lung cancer care by critically evaluating the latest NCCN guidelines, tumour molecular profiling, and MDT approaches to develop tailored treatment plans that optimise patient outcomes.
- Evaluate the efficacy of advanced therapies, including stereotactic body radiotherapy (SBRT), minimally invasive surgical approaches, oncological targeted therapies etc. through the assessment of real case studies to determine their impact on early-stage and complex lung cancer cases.
- Synthesise regional and global best practices in lung cancer care by fostering collaboration and networking, enabling attendees to apply these insights to enhance the standard of care and patient access to innovative treatments across the GCC.